Citation

García-Rizo C, Fernandez-Egea E, Oliveira C, Meseguer A, Cabrera B, Mezquida G, Bioque M, Penadés R, Parellada E, Bernardo M, Kirkpatrick B. Eur. Psychiatry 2017; 41: 42-46.

Copyright

(Copyright © 2017, Elsevier Publishing)

DOI

10.1016/j.eurpsy.2016.10.001

PMID

28049080

Abstract

Patients with schizophrenia exhibit a reduced life expectancy. Although unhealthy lifestyle or suicide risk plays a role, the main causes are diverse medical conditions such as cardiovascular diseases, type 2 diabetes mellitus and metabolic syndrome. Albeit pharmacological secondary side effects might also trigger previous conditions, studies in naïve patients reflect diverse anomalies at the onset. Patients with a first episode of psychosis, display a wide scope of metabolic abnormalities, ranging from normality till pathological values depending on the parameters studied. We attempted to evaluate the metabolic syndrome and glycemic homeostasis in a subset of antipsychotic-naïve patients with a first episode of non-affective psychosis. Patients (n=84) showed a similar prevalence of metabolic syndrome compared with a matched control sample (n=98) (6% vs 4%, P=0.562), while glucose homeostasis values differed significantly (14% vs. 5%, P=0.034). Our results suggest that metabolic syndrome is not a useful clinical condition to be evaluated in patients before pharmacological treatment. Abnormal glycemic homeostasis at the onset of the disease requires specific diagnostic tools and preventive measures in order to avoid future cardiovascular events. New strategies must be implemented in order to evaluate the cardiovascular risk and subsequent morbidity in patients at the onset of the disease.

Language: en

Keywords

Humans; Risk Factors; Adult; Female; Male; Spain; Cardiovascular Diseases; Prevalence; Schizophrenia; Psychosis; Psychotic Disorders; Metabolic syndrome; Antipsychotic Agents; First episode; Blood Glucose; Metabolic Syndrome; Antipsychotic-naïve; Oral glucose tolerance test; Thrifty psychiatric phenotype